

Special Issue

Blood Stem Cell and Hematological Malignancies (Second Edition)

Message from the Guest Editor

This Special Issue is the second edition of a previous Special Issue entitled “Blood Stem Cell and Hematological Malignancies”

(https://www.mdpi.com/journal/cancers/special_issues/RX9Q813G37).

Hematopoietic stem cells (HSCs) are critical for the lifelong production of blood. Although clonal evolution ultimately drives the progression of every disease, the process itself is still poorly understood. A better understanding of hematopoietic stem cell biology in health and disease is thus needed to prevent and delay clonal evolution, limit disease progression, and develop better treatments.

In this Special Issue, we are pleased to invite you to contribute your latest findings, share exciting novel insights, and summarize the current research of your field of research. This Special Issue aims to highlight recent research advances in hematopoietic stem cell biology, including their role in hematological malignancies, clonal hematopoiesis, myelodysplastic syndromes, and the part played by cell-intrinsic vs. cell-extrinsic factors in disease progression. In this Special Issue, original research articles and reviews are welcome.

Guest Editor

Dr. Dirk Loeffler

1. Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

2. Department of Pathology and Laboratory Medicine, The University of Tennessee, Memphis, TN 38163, USA

Deadline for manuscript submissions

30 May 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/251472

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)